511 related articles for article (PubMed ID: 24683168)
1. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
[TBL] [Abstract][Full Text] [Related]
2. Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery.
Pasqual EM; Bertozzi S; Bacchetti S; Londero AP; Basso SM; Santeufemia DA; Lo Re G; Lumachi F
Anticancer Res; 2014 May; 34(5):2363-8. PubMed ID: 24778044
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Pfannenberg C; Königsrainer I; Aschoff P; Oksüz MO; Zieker D; Beckert S; Symons S; Nieselt K; Glatzle J; Weyhern CV; Brücher BL; Claussen CD; Königsrainer A
Ann Surg Oncol; 2009 May; 16(5):1295-303. PubMed ID: 19252950
[TBL] [Abstract][Full Text] [Related]
4. Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy.
Berthelot C; Morel O; Girault S; Verrièle V; Poirier AL; Moroch J; Boucher Y; Le Jeune JJ; Lorimier G
Nucl Med Commun; 2011 Jan; 32(1):23-9. PubMed ID: 21042225
[TBL] [Abstract][Full Text] [Related]
5. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
6. Pitfalls and mimickers on (18)F-FDG-PET/CT in peritoneal carcinomatosis from colorectal cancer: An analysis from 37 patients.
Audollent R; Eveno C; Dohan A; Sarda L; Jouvin I; Soyer P; Pocard M
J Visc Surg; 2015 Nov; 152(5):285-91. PubMed ID: 26115889
[TBL] [Abstract][Full Text] [Related]
7. Reply to: Use of FDG PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy: some considerations.
Campos PA; Gil J; Parrilla P
Nucl Med Commun; 2011 May; 32(5):421. PubMed ID: 21467875
[No Abstract] [Full Text] [Related]
8. Clinical Value of (18)F-FDG- PET-CT in the Preoperative Staging of Peritoneal Carcinomatosis from Colorectal Origin.
De Vos N; Goethals I; Ceelen W
Acta Chir Belg; 2014; 114(6):370-5. PubMed ID: 26021680
[TBL] [Abstract][Full Text] [Related]
9. Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI.
Klumpp BD; Schwenzer N; Aschoff P; Miller S; Kramer U; Claussen CD; Bruecher B; Koenigsrainer A; Pfannenberg C
Abdom Imaging; 2013 Feb; 38(1):64-71. PubMed ID: 22476333
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
11. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
12. Recurrent thyroid cancer diagnosis: ROC study of the effect of a high-resolution head and neck 18F-FDG PET/CT scan.
Chatziioannou SN; Georgakopoulos AT; Pianou NK; Kafiri GT; Pavlou SN; Kallergi M
Acad Radiol; 2014 Jan; 21(1):58-63. PubMed ID: 24331265
[TBL] [Abstract][Full Text] [Related]
13. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
14. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Sommariva A; Evangelista L; Pintacuda G; Cervino AR; Ramondo G; Rossi CR
Abdom Radiol (NY); 2018 May; 43(5):1094-1100. PubMed ID: 28770289
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG PET/CT, cytoreductive surgery and intraperitoneal chemohyperthermia for the therapeutic management in peritoneal carcinomatosis: A pilot study.
Cistaro A; Cucinotta M; Cassalia L; Priola A; Priola S; Pappalardo M; Coppolino P; De Simone M; Quartuccio N
Rev Esp Med Nucl Imagen Mol; 2016; 35(4):232-7. PubMed ID: 26907833
[TBL] [Abstract][Full Text] [Related]
17. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
18. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT.
Dirisamer A; Schima W; Heinisch M; Weber M; Lehner HP; Haller J; Langsteger W
Eur J Radiol; 2009 Mar; 69(3):536-41. PubMed ID: 18248928
[TBL] [Abstract][Full Text] [Related]
19. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer.
Strobel K; Heinrich S; Bhure U; Soyka J; Veit-Haibach P; Pestalozzi BC; Clavien PA; Hany TF
J Nucl Med; 2008 Sep; 49(9):1408-13. PubMed ID: 18703604
[TBL] [Abstract][Full Text] [Related]
20. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
